Lv5
1500 积分 2021-03-22 加入
Advancing AI for multi-omics and clinical data integration in basic and translational cancer research
12天前
已完结
Fulzerasib plus cetuximab in first-line KRAS-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial
29天前
已完结
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies
1个月前
已关闭
Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2–Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial
1个月前
已完结
Artificial intelligence-generated synthetic data for cancer research and clinical trials
2个月前
已完结
TIGIT’s immuno-oncology teachings
2个月前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
2个月前
已完结
Discovery of predictive biomarkers for cancer therapy through computational approaches
4个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
4个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
4个月前
已完结
皖公网安备34019202002308
